NRX Pharmaceuticals, Inc. (GETTEX:B1Q) Financings
Financings
| Raise | Date |
|---|---|
| Strategic investment of restricted common stock Closed: US$6.5M raised Buyers: B Group Capital (Led a consortium of biotechnology investors purchasing approximately 3.9 million shares for $6.5 million) Use of proceeds: Capital to reach expected regulatory inflection points | Aug 18, 2025 |
| Debt financing Update: US$7.8M Buyers: Universal Capital, LLC ($7.8 million in debt financing) Use of proceeds: HOPE Therapeutics clinic acquisitions, starting with Dura Medical, Kadima and NeuroSpa clinics | May 28, 2025 |
| Strategic investment of series A Convertible Preferred Stock of HOPE Therapeutics Announced: US$2.5M Use of proceeds: Support the launch of HOPE's clinic network and the closing of its announced clinic acquisitions | Apr 3, 2025 |
| Strategic investment of nRx common stock Cancelled: US$2M · US$2.75 a share · Warrants at US$3 for 24 months Buyers: Smith & Sauer ($2 million in NRx common stock at $2.75 per share); Smith and Sauer ($2.0 million in NRx common stock) Use of proceeds: To advance the new drug applications for NRX-100 and NRX-101 | Mar 17, 2025 |
| Strategic investment of series A Preferred Stock of HOPE Therapeutics Update: US$25M Buyers: Smith & Sauer, LLC ($25 million equity purchases in HOPE Therapeutics Series A Preferred Stock); Smith and Sauer ($25 million in newly issued Series A Preferred Stock of HOPE) Use of proceeds: To fund planned acquisitions of HOPE interventional psychiatry clinics in a nationwide rollup | Jan 28, 2025 |
| Registered direct offering of common stock with common stock purchase warrants Announced: US$3.5M · US$2.88 a share · Warrants at US$2.88 Buyers: Anson Funds Use of proceeds: New Drug Application filings for NRX-100 and NRX-101, launch of HOPE Therapeutics, and potential new pipeline products | Jan 28, 2025 |
| Senior secured convertible promissory notes Announced: US$5.4M · Warrants at US$3.78 Buyers: Anson Funds Use of proceeds: New Drug Application filings for NRX-100 and NRX-101, launch of HOPE Therapeutics, and potential new pipeline products | Jan 28, 2025 |